<DOC>
	<DOCNO>NCT00289536</DOCNO>
	<brief_summary>The purpose study determine effect 3 dos ADVATE rAHF-PFM initial recovery ( % increase [ IU/dL ] per IU/kg infuse ) major single-infusion pharmacokinetic parameter . The 3 dos 15 , 30 , 50 IU/kg . Prior infusion , subject receive treatment factor VIII concentrate least 3 day . Blood sample draw within 30 minute pre-infusion 0.25 , 0.5 , 1 , 3 , 6 , 9 , 24 , 28 , 32 48 hour post-infusion . A washout period least 3 day , 30 day last blood draw next infusion observe . During participation , subject maintain preexist treatment regimen ADVATE rAHF-PFM factor VIII concentrate . A secondary objective investigate relationship pharmacokinetic parameter dose level level von Willebrand factor ristocetin cofactor activity von Willebrand factor antigen baseline .</brief_summary>
	<brief_title>Dose-Response Study Recombinant Factor VIII Manufactured Protein-Free ( rAHF-PFM ) Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject severe hemophilia A define baseline factor VIII activity &lt; 1 % normal ; test screening . ( A minimum washout period 3 day require blood sample drawn determine baseline factor VIII level . ) The subject document history least 150 exposure day factor VIII concentrate ( either plasmaderived recombinant ) . The subject within 12 65 year age . The subject Karnofsky performance score &gt; 60 . The subject human immunodeficiency virus negative ( HIV ) HIV+ CD4 count &gt; =400 cells/mm3 ( CD4 count determine screening , necessary ) . The subject subject´s legally authorize representative provide write informed consent . The subject know hypersensitivity mouse hamster protein factor VIII concentrate . The subject history factor VIII inhibitor titer &gt; =0.8 BU ( Bethesda Assay ) &gt; =0.4 BU ( Nijmegen modification Bethesda Assay ) time prior screening . The subject detectable factor VIII inhibitor screening , &gt; =0.4 BU ( Nijmegen modification Bethesda Assay ) , Baxter central laboratory . The subject severe chronic liver disease evidence , limited , follow : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varix . The subject diagnose inherit acquire hemostatic defect hemophilia A ( e.g . qualitative platelet defect von Willebrand´s Disease ) . The subject participate another investigational study within 30 day enrollment . The subject´s clinical condition may require major moderate surgery ( estimate blood loss &gt; 500 mL ) period participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>